๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Kunming
Clinical trial register · China

Clinical Trials in Kunming, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Yunnan Cancer Hospital18 AstraZeneca14 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China6 First Affiliated Hospital of Kunming Medical University5 The Second Affiliated Hospital of Kunming Medical University5
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Kunming

193 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adult Aged 18 Years and Above
NCT06645665Respiratory Syncytial Virus Infections
Shenzhen Shenxin Biotechnology Co., Ltd
Phase 1
240
Shanghai, Kunming
2024-11-11
Recruiting
Fufang Congrong Yizhi Capsules (FCYC) of Cognitive Impairment After Intracerebral Hemorrhage
NCT06673602Cognitive Impairment, Intracerebral Hemorrhage
Qinhuangdao Hospital of Traditional Chinese Medicine
Phase 4
200
Beijing, Qinhuangdao, Kaifeng, Jinan, Weifang, Kunming
2024-11-04
Not yet open
Retrospective Analysis of Clinical and CT Features to Predict Spread Through Air Space in Stage IA Lung Adenocarcinoma
NCT06645743Tomography, X-Ray Computed, Spread Through Air Space, Clinical Features, Stage IA Adenocarcinoma of Lung
The Third Affiliated Hospital of Kunming Medical College.
Observational
1,100
Kunming
2024-10-25
Active, closed
An Open Label Study of Gene Therapy Product (Vesemnogene Lantuparvovec) in Spinal Muscular Atrophy
NCT06288230Spinal Muscular Atrophy
Lantu Biopharma
Phase 1/2
20
Kunming
2024-10-20
Active, closed
A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China
NCT06640049Neoplasms, Rectal
DrugDostarlimab
GlaxoSmithKline
Phase 2
23
Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Kunming, Shanghai
2024-10-17
Recruiting
Efficacy of Self-expandable and Balloon-expandable Valves in Patients With Ascending Aortic Dilation
NCT06743568Aortic Stenosis, Ascending Aortic Dilatation
China National Center for Cardiovascular Diseases
Not applicable
100
Beijing, Shenzhen, Kunming
2024-10-15
Recruiting
JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE)
NCT06675422Systemic Lupus Erythematosus (SLE)
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase 1/2
20
Kunming
2024-10-09
Recruiting
Tumor-Targeted-NIR-II Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Metastatic Status
NCT06713161Breast Cancer, Sentinel Lymph Node, Metastases, Margin Assessment
Yunnan Cancer Hospital
Observational
40
Kunming
2024-09-01
Recruiting
A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors.
NCT06487455Advanced Solid Tumor
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1
170
Changsha, Fuzhou, Hangzhou, Kunming, Shanghai, Wuhan
2024-08-06
Recruiting
PulseSelectโ„ข PFA Global Registry
NCT06393920Atrial Fibrillation
Medtronic Cardiac Ablation Solutions
Observational
1,950
Beijing, Fuzhou, Harbin, Kunming, Nanjing, Shanghai, Shenzhen, รœrรผmqi
2024-07-23
Recruiting
The Study is an Observational Post-market Follow-up Program to Evaluate Long Term (5 Years) Safety of Mentor Breast Implants in Chinese Population
NCT06510205Breast Augmentation, Mammaplasty
Johnson & Johnson Medical (Shanghai) Ltd.
Observational
6,111
Chengdu, Kunming, Shenzhen
2024-07-14
Active, closed
Efficacy, Safety and Immunogenicity Study of Recombinant Zoster Vaccine(CHO Cell) in Adults Aged 40 Years and Older
NCT06447779Herpes Zoster
DrugRecombinant Zoster Vaccine
MAXVAX Biotechnology Limited Liability Company
Phase 3
25,000
Shijiazhuang, Zhengzhou, Wuhan, Kunming
2024-07-13
Recruiting
A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.
NCT06434610Platinum-resistant Recurrent Ovarian Cancer
DrugPaclitaxel
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2
90
Beijing, Bengbu, Changsha, Fuzhou, Guangzhou, Jinan, Kunming, Nanning
2024-07-11
Active, closed
A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males
NCT06465914Genital Wart, Penile Cancer, Anal Cancer, PIN-1
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3
9,000
Nanning, Changsha, Taiyuan, Chengdu, Kunming
2024-07-11
Recruiting
Effects of Different Inhaled Oxygen Concentrations on Lung Function in Older Patients After Laparoscopic Gastrointestinal Surgery Under General Anesthesia
NCT06359106Oxygenation Index
China Medical University, China
Phase 4
1,176
Shenyang, Beijing, Chendu, Chifeng, Dalian, Harbin, Jinan, Kunming
2024-07-02
Recruiting
The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP
NCT06390306Chronic Myeloid Leukemia
DrugsPonatinib·Olverembatinib·Azacitidine·Venetoclax
Peking University People's Hospital
Observational
30
Beijing, Chengdu, Guangdong, Kunming, Nanjing, Nanning, Nanyang, Ningbo
2024-07-01
Recruiting
Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
NCT06515262Relapsed/Refractory Multiple Myeloma
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Not applicable
10
Kunming
2024-07-01
Not yet open
Catheter Ablation of Haemodynamically Not-tolerated Electrical Storm in Structural Heart Disease
NCT06455020Ventricular Tachycardia
Beijing Anzhen Hospital
Not applicable
96
Beijing, Changsha, Kunming, Nanjing
2024-07-01
Recruiting
A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
NCT06447597Generalized Myasthenia Gravis
DrugB007
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
104
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Kunming
2024-07-01
Recruiting
Guo's Aortic Arch Reconstruction: A Multicenter, Prospective Study of the Novel WeFlow-Tribranch System (GENIUS Study)
NCT06385379Aortic Arch Aneurysm
Hangzhou Endonom Medtech Co., Ltd.
Not applicable
90
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Harbin, Jinan, Kunming
2024-06-30
Recruiting
JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)
NCT06514768B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugJY231
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase EARLY_PHASE1
20
Kunming
2024-06-20
Recruiting
Concave Supra-arch Branched Stent-Graft System for Endovascular Treatment of Aortic Arch Diseases
NCT06520774Aortic Arch Aneurysm, Penetrating Aortic Ulcer
Lifetech Scientific (Shenzhen) Co., Ltd.
Not applicable
103
Beijing, Changsha, Chengdu, Fuzhou, Hanzhou, Kunming, Nanjing, Shanghai
2024-05-30
Active, closed
An Open-label Study of a Gene Therapy Product (Vebeglogene Autotemcel) in Transfusion Dependent Beta-Thalassemia
NCT06308159Beta-Thalassemia
Lantu Biopharma
Phase 1/2
6
Kunming
2024-05-11
Recruiting
Research on Body Voice AI Recognition System for Children's Health Management
NCT06542120Congenital Heart Disease, Bronchopneumonia, Abdominal Disease
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Observational
30,000
Wuhan, Changsha, Shanghai, Kunming
2024-05-01
Recruiting
A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
NCT06403735Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor
Qilu Pharmaceutical Co., Ltd.
Phase 1
250
Guangzhou, Harbin, Nanchang, Shanghai, Kunming
2024-04-25
Active, closed
Evolve China PMCF Study
NCT06368622Intracranial Aneurysm
Stryker Neurovascular
Observational
500
Beijing, Changchun, Fuzhou, Guangzhou, Kunming, Nanyang, Ningbo, Qingdao
2024-04-24
Recruiting
CtDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial)
NCT06242418Colon Cancer
DrugsFolfoxiri·Xelox
West China Hospital
Phase 2
60
Guiyang, Chengde, Chengdu, Kunming
2024-03-25
Recruiting
Clinical Study on Modified Allogeneic Hematopoietic Stem Cell Transplantation Regimen for Severe Aplastic Anemia
NCT06378060Severe Aplastic Anemia
Hematology department of the 920th hospital
Phase 2
30
Kunming
2024-03-01
Recruiting
Risk Factors for Postoperative Cough in Patients Undergoing Thoracoscopic Lung Resection
NCT06476249Lung Cancer
Hematology department of the 920th hospital
Observational
1,000
Kunming
2024-03-01
Recruiting
Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)
NCT06352281ITP - Immune Thrombocytopenia
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase 1/2
10
Kunming
2024-02-01
Active, closed
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
NCT06163326Vitiligo
DrugRitlecitinib
Pfizer
Phase 3
394
Guangzhou, Wuhan, Shenyang, Shanghai, Kunming
2024-01-19
Recruiting
Multi-omics Study for Early Detection of Colorectal Cancer (MOED-CRC)
NCT06220617Colorectal Cancer, Adenomatous Polyps, Adenoma, Advanced Adenoma
Zhejiang University
Observational
3,600
Hangzhou, Guangzhou, Kunming, Nanjing, Xi'an, Zhengzhou
2024-01-11
Recruiting
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
NCT05950945Breast Cancer
DrugTrastuzumab deruxtecan
Daiichi Sankyo
Phase 3
250
Beijing, Fujian, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanchang
2023-12-30
Recruiting
Feasibility Study of Deep Learning-based MDixon Quant for Quantitative Assessment of Chemotherapy-induced Fatty Liver
NCT06735118Non-Alcoholic Fatty Liver Disease
Yunnan Cancer Hospital
Not applicable
120
Kunming
2023-12-25
Recruiting
Study on the Value of Three DWI Scanning Sequences in Staging of Gastric Cancer
NCT06735105Gastric Cancer
Yunnan Cancer Hospital
Not applicable
129
Kunming
2023-12-23
Recruiting
Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
NCT06155383Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsDisitamab Vedotin·Oxaliplatin·Capecitabine·Tislelizumab
RemeGen Co., Ltd.
Phase 2
90
Beijing, Fuzhou, Kunming, Xiamen, Wuwei, Guangzhou, Harbin, Zhengzhou
2023-11-27
Active, closed
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
NCT06097728Unresectable Pleural Mesothelioma
DrugsVolrustomig·Ipilimumab·Nivolumab·Pemetrexed
AstraZeneca
Phase 3
863
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Kunming, Lanzhou
2023-11-09
Recruiting
Study of Adrenocorticotropic Hormone on Children With Frequent Relapse or Steroid-dependent Nephrotic Syndrome: a Prospective, Multicenter, Randomized๏ผŒOpen-label Clinical Trial.
NCT06079788Nephrotic Syndrome in Children
Mao Jianhua
Phase 3
140
Wuhan, Nanjing, Kunming, Hangzhou, Ningbo, Wenzhou, Beijing, Shanghai
2023-11-01
Recruiting
A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation
NCT06102928Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Kunming Medical University
Not applicable
30
Kunming
2023-10-30
Recruiting
The Efficacy of Watch and Wait Strategy or Surgery After Neoadjuvant Immunotherapy for Locally Advanced Colorectal Cancer With dMMR/MSI-H Guided by MRD Dynamic Monitoring: A Single-center, Open-label, Prospective, Phase II Clinical Trial.
NCT06477991Clinical Complete Response Rate With Negative MRD
Yunnan Cancer Hospital
Observational
22
Kunming
2023-10-30
Recruiting
Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies
NCT05991908Acute Myeloid Leukemia, Myelodysplastic Syndromes
DrugFludarabine and Busulfan
Shanghai Jiao Tong University School of Medicine
Phase 3
222
Fuzhou, Xiamen, Nanning, Nanjin, Suzhou, Shanghai, Kunming
2023-10-19
By invitation
A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT06044337Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
DrugLitifilimab
Biogen
Phase 3
306
Beijing, Shenzhen, Dongguan, Guangzhou, Changsha, Nanjing, Shanghai, Kunming
2023-10-03
Recruiting
AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
NCT06035250Gastric Cancer, Image, Pathology
Chinese Academy of Sciences
Observational
200
Beijing, Changsha, Fuzhou, Guangzhou, Kunming, Nanning, Qingdao, Shanghai
2023-09-10
Active, closed
Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis
NCT06174402Primary Biliary Cholangitis
Han Ying
Phase 2/3
184
Lanzhou, Guangzhou, Nanjing, Shenyang, Xi'an, Yanโ€™an, Kunming, Beijing
2023-08-21
Active, closed
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years
NCT06041061HPV InfectioN, HPV-Related Carcinoma
Sinocelltech Ltd.
Phase 3
18,000
Nanning, Zhengzhou, Taiyuan, Chengdu, Kunming
2023-08-13
Recruiting
Safety and Efficacy of Ceraโ„ข Patent Foramen Ovale Occluders.
NCT05774288Patent Foramen Ovale, Cryptogenic Stroke
Lifetech Scientific (Shenzhen) Co., Ltd.
Not applicable
244
Beijing, Guangzhou, Meizhou, Changsha, Changchun, Shenyang, Jinan, Kunming
2023-06-08
Recruiting
The Efficacy and Safety of Intracranial Stent (Tonbridge) in Endovascular Treatment of Symptomatic Intracranial Atherosclerotic Stenosis
NCT05757505Intracranial Atherosclerosis
Ton-Bridge Medical Tech. Co., Ltd
Not applicable
200
Luoyang, Wuhan, Nanjing, Nanchang, Changchun, Dalian, Baotou, Kunming
2023-05-11
Active, closed
Long COVID and Its Associations With Health Outcomes in Older Adults
NCT05825651Long COVID, COVID-19 Pandemic, Elderly Infection, Vaccine Reaction
Peking University
Observational
11,527
Kunming
2023-04-24
Active, closed
Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm
NCT05546866Non-small Cell Lung Cancer
DrugOsimertinib
AstraZeneca
Phase 2
51
Beijing, Chengdu, Fuzhou, Guangzhou, Kunming, Ningbo, Shijiazhuang, Suzhou
2023-02-09
Recruiting
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT05702229Gastric Cancer
DrugsSonesitatug vedotin·Volrustomig·Xelox·Rilvegostomig
AstraZeneca
Phase 2
163
Beijing, Hangzhou, Harbin, Hefei, Kunming, Wuhan, Yinchuan, Zhengzhou
2023-01-16
Recruiting
Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
NCT05722275Gastric Cancer, Peritoneal Metastases
Chinese Academy of Sciences
Observational
400
Beijing, Fuzhou, Guangzhou, Guiyang, Kunming, Taiyuan, Zhengzhou, Zhenjiang
2023-01-01
Active, closed
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266NSCLC
DrugsDatopotamab deruxtecan·Dato-DXd·Durvalumab·Pemetrexed
AstraZeneca
Phase 3
1,350
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hefei, Jinan, Kunming
2022-12-29
Active, closed
A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (ฮฑ)-Thalassemia
NCT05664737Anemia
DrugLuspatercept
Bristol-Myers Squibb
Phase 2
189
Guangzhou, Foshan, Maoming Shi, Shenzhen Shi, Liuzhou, Nanning, Haikou, Kunming
2022-12-09
Active, closed
Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC
NCT05374603Lung Cancer
DrugsSavolitinib·Durvalumab
AstraZeneca
Phase 2
47
Beijing, Changsha, Chongqing, Hangzhou, Jinan, Kunming, Nanchang, Ningbo
2022-11-15
Active, closed
A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (ฮฒ)-Thalassemia.
NCT05567458Beta-thalassemia
DrugLuspatercept
Bristol-Myers Squibb
Phase 2
94
Maoming, Shenzhen, Liuzhou, Nanning, Haikou, Kunming, Guangzhou
2022-10-17
Recruiting
Epidemiology of Abdominal Aortic Aneurysm With Concomitant Primary Lung Cancer
NCT06775821Abdominal Aortic Aneurysm, Primary Lung Cancer, Prevalence
First Affiliated Hospital of Kunming Medical University
Observational
2,000
Kunming
2022-10-01
Recruiting
Patient-Reported Outcome and Safety Between Preoperative and Postmastectomy Radiotherapy in DIEP Flap Reconstruction
NCT05512286Breast Cancer
Fudan University
Not applicable
80
Nanning, Zhengzhou, Changsha, Shanghai, Kunming, Hangzhou
2022-08-25
Active, closed
Roll-over Study to Allow Continued Access to Ribociclib
NCT05161195Metastatic Breast Cancer
DrugsGoserelin·Tamoxifen·Anastrozole·Ribociclib
Novartis Pharmaceuticals
Phase 4
134
Chongqing, Shijiazhuang, Harbin, Changsha, Nanjing, Suzhou, Changchun, Kunming
2022-07-07
Active, closed
A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium
NCT05456425Pterygium
Cloudbreak Therapeutics, LLC
Phase 3
660
Beijing, Chengdu, Haikou, Hengyang, Kunming, Nanchang, Qingdao, Wenzhou
2022-06-30
Active, closed
SQ-Kyrin-T First-in-man Feasibility Study
NCT06605313Tricuspid Regurgitation
Shanghai Shenqi Medical Technology Co., Ltd
Not applicable
12
Kunming
2022-06-16
Recruiting
TAPP and Open Repair for Recurrent Inguinal Hernia
NCT06604572Recurrent Inguinal Hernia
The Second Affiliated Hospital of Kunming Medical University
Not applicable
70
Kunming
2022-05-01
Active, closed
A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China
NCT05662020Human Papillomavirus Infection
Beijing Health Guard Biotechnology, Inc
Phase 3
2,750
Kunming
2022-03-23
Active, closed
A Clinical Investigation to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery Disease
NCT05206084Coronary Artery Disease
Biotyx Medical (Shenzhen) Co., Ltd.
Not applicable
518
Kunming
2022-03-10
Active, closed
A Clinical Trial to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery Disease
NCT05205499Coronary Artery Disease
Biotyx Medical (Shenzhen) Co., Ltd.
Not applicable
1,059
Kunming
2022-03-10
Active, closed
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
NCT05221840Non-Small Cell Lung Cancer
DrugsMonalizumab·Oleclumab·Durvalumab
AstraZeneca
Phase 3
1,051
Anyang, Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Hefei, Kunming
2022-02-07
By invitation
A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
NCT05076617Stereotypical Prolonged Seizures
DrugStaccato alprazolam
UCB Biopharma SRL
Phase 3
300
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Kunming
2022-02-03
Active, closed
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
NCT04954859Hepatitis B
DrugBepirovirsen
GlaxoSmithKline
Phase 2
360
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Kunming, Liuzhou
2021-12-14
Recruiting
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
NCT05077904Stereotypical Prolonged Seizures
DrugStaccato alprazolam
UCB Biopharma SRL
Phase 3
350
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Kunming
2021-12-07
Active, closed
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
NCT05113251Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
DrugsPertuzumab·Trastuzumab deruxtecan·Doxorubicin·Trastuzumab
AstraZeneca
Phase 3
927
Beijing, Changsha, Chongqing, Guangzhou, Kunming, Nanning, Qingdao, Shanghai
2021-10-25
Recruiting
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
NCT05123482Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer
DrugsPalacaparib·Saruparib·Rilvegostomig
AstraZeneca
Phase 1/2
460
Beijing, Changsha, Chongqing, Guangzhou, Kunming, Shandong
2021-10-18
Active, closed
Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer
NCT04922853Rectal Cancer, Neoadjuvant Chemotherapy
West China Hospital
Phase 3
554
Wuxi, Chengdu, Kunming
2021-08-26
Active, closed
Guo's Aortic Arch Reconstruction :The Prospective ,Multiple Center Study About the Safety and Efficacy of WeFlow-Arch Modeler Embedded Branch Stent Graft System (GIANT Study)
NCT04765592Aortic Arch Aneurysm
Hangzhou Endonom Medtech Co., Ltd.
Not applicable
88
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Kunming
2021-06-07
Active, closed
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
NCT04586010Relapsing Multiple Sclerosis
DrugsFenebrutinib·Teriflunomide
Hoffmann-La Roche
Phase 3
746
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Kunming
2021-03-17
Recruiting
a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
NCT04776330Multiple Myeloma, Neoplasm, Plasma Cell, Multiple Myeloma in Relapse
Chongqing Precision Biotech Co., Ltd
Phase 1/2
80
Kunming
2021-03-07
Recruiting
a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL
NCT04781634B-ALL
Chongqing Precision Biotech Co., Ltd
Phase 1/2
40
Kunming
2021-03-07
Active, closed
Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus
NCT04582136Systemic Lupus Erythematosus
DrugPaclitaxel
Chinese SLE Treatment And Research Group
Phase 3
146
Beijing, Shenzhen, Zhengzhou, Nanchang, Shenyang, Kunming
2021-03-04
Active, closed
Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A
NCT04644575Hemophilia A
DrugEfanesoctocog alfa
Bioverativ, a Sanofi company
Phase 3
261
Beijing, Guangzhou, Hangzhou, Jinan, Kunming, Lanzhou, Suzhou
2021-02-23
Active, closed
Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection
NCT04666272Melanoma
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Observational
78
Fuzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Kunming, Hangzhou, Beijing
2020-12-31
Active, closed
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
NCT04351555Non-Small Cell Lung Cancer
DrugsTagrisso·Osimertinib·Pemetrexed·Cisplatin
AstraZeneca
Phase 3
358
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Kunming, Nanchang
2020-12-16
Active, closed
Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
NCT04562766Immune Thrombocytopenia
DrugRilzabrutinib
Principia Biopharma, a Sanofi Company
Phase 3
232
Wuhan, Shenyang, Xi'an, Jinan, Tianjin, Kunming, Hangzhou, Hefei
2020-12-14
Active, closed
Angiography-Derived FFR And IVUS for Clinical Outcomes in Patients With Coronary Artery Disease
NCT04397211Coronary Artery Disease
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,872
Hangzhou, Beijing, Guangdong, Huzhou, Jinan, Jinhua, Kunming, Nanchang
2020-05-29
Recruiting
Plasmodium Immunotherapy for Advanced Malignant Solid Tumors
NCT04165590Advanced Malignant Solid Tumor
CAS Lamvac Biotech Co., Ltd.
Phase 1/2
60
Kunming
2019-10-24
Active, closed
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
NCT04008797Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms
DrugsE7386·Doxorubicin·Lenvatinib·Paclitaxel
Eisai Inc.
Phase 1/2
301
Beijing, Changchun, Fuzhou, Guangzhou, Jinan, Kunming, Shanghai, Shenzhen
2019-07-11
Recruiting
Construction of a Multi-center Clinical Research Collaboration Network for Children with Congenital Heart Disease in China
NCT06885307Congenital Heart Disease (CHD)
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Observational
35,000
Wuhan, Xining, Shanghai, Kunming, Wenzhou, Jinan
2019-06-01
Recruiting
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
NCT04271644Multiple Myeloma, Neoplasm, Plasma Cell, Multiple Myeloma in Relapse
Chongqing Precision Biotech Co., Ltd
Phase 1/2
80
Kunming
2019-04-01
Active, closed
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX
NCT03754790Hemophilia
DrugFitusiran
Genzyme, a Sanofi Company
Phase 3
281
Beijing, Changsha, Chengdu, Guangzhou, Guiyang, Hangzhou, Jinan, Kunming
2019-01-09
Active, closed
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
NCT03040973Advanced Solid Tumors Which Are cMET-dependent
DrugsCapmatinib·Gefitinib·Osimertinib
Novartis Pharmaceuticals
Phase 2
29
Shanghai, Kunming
2017-07-04
Recruiting
Multicenter Cohort Study on Osteoporosis
NCT02958020Osteoporosis
Shanghai University of Traditional Chinese Medicine
Observational
50,000
Shenzhen, Ganzhou, Jinan, Kunming, Beijing, Changchun, Guangzhou, Lanzhou
2016-11
Active, closed
AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.
NCT02511106Stage IB-IIIA Non-small Cell Lung Carcinoma
DrugOsimertinib
AstraZeneca
Phase 3
682
Beijing, Changchun, Dalian, Guangzhou, Hangzhou, Kunming, Nanjing, Nanning
2015-10-21
Recruiting
Perioperative IL-33 is Associated with the Early Stage of Postoperative Neurocognitive Dysfunction After Major Abdominal Surgery
NCT06704451Postoperative Neurocognitive Dysfunction, Cognitive Dysfunction, Postoperative Complications, Neuropsychological Tests
First Affiliated Hospital of Kunming Medical University
Observational
150
Kunming
2014-08-18
Recruiting
Product Surveillance Registry
NCT01524276Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders
Medtronic
Observational
100,000
Nanning, Chengdu, Beijing, Dalian, Guangzhou, Hangzhou, Harbin, Kunming
2012-01
Active, closed
A Clinical Study of the Effects of Environmental Pollution on Obesity
NCT06670703Obesity and Overweight
Dong Peng
Observational
800
Chongqing, Kunming
2011-01-01
Recruiting
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
NCT00271180Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
Medtronic
Observational
20,000
Beijing, Changsha, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming
1983-01
Rows per page Showing 101–193 of 193
Previous 1 2
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/kunming?page=2

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 193 of those studies with a site in Kunming.

How many clinical trials are recruiting in Kunming?

98 of the 193 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 36 have not yet opened recruitment, 54 are active but closed to new participants, and 5 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.